Boston Scientific reaches preliminary settlement of derivative lawsuits over LOTUS Edge recall

BOSTON SCIENTIFIC CORP

On January 8, 2025, a U.S. district court granted preliminary approval of a settlement of two shareholder derivative actions related to the LOTUS Edge recall.
The proposed settlement, dated September 6, 2024, includes corporate governance reforms such as amendments to committee charters and insider trading policy.
A final approval hearing is scheduled for March 25, 2025 at 2:00 p.m. Eastern Time.
The derivative lawsuits alleged breaches of fiduciary duty and violations related to the prior recall and retirement of the LOTUS Edge Aortic Valve System.
Under the settlement, Boston Scientific will adopt governance reforms to remain in effect for at least three years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.